Search results
Bain Capital Life Sciences invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs.
Bain Capital Life Sciences seeks to create differentiated value by identifying investments in companies that have these key features: Research organizations that drive innovation across the healthcare value chain.
Aug 16, 2021 · ESG & Impact. Newsroom. Bain Capital, LPis one of the world’s leading private investment firms with approximately $185 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live.
Series C financing led by Bain Capital Life Sciences to support PKU program and pipeline in immune-mediated diseases and cancer; Ron Renaud joins Jnana's Board of DirectorsJnana initiates Phase 1 clinical trial of JNT-517, a potential first-in-class oral treatment for PKU; JNT-517 receives US FDA Rare Pediatric Disease DesignationBOSTON – Nov ...
News | Bain Capital Life Sciences. Scroll up to People. See all Life Sciences news >.
Aug 16, 2021 · Bain Capital’s life sciences arm has just finished raising $1.9 billion for its third investment fund, including $300 million from current and former partners of the Boston-based private equity ...
Aug 17, 2021 · Published: Aug 17, 2021 By Vanessa Doctor, RN. The life sciences arm of Boston-based private equity firm Bain Capital has successfully raised $1.9 billion to fund future projects that involve medical, drug, and biotechnology projects. The initiative was spearheaded by the 16-person team at Bain Capital Life Sciences with the goal to find and ...
